R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry

dc.contributor.author

DiMasi, Joseph A

dc.contributor.author

Vernon, John

dc.contributor.author

Grabowski, Henry

dc.date.accessioned

2013-04-23T16:46:07Z

dc.date.issued

1995-01-01

dc.description.abstract

This study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Project-level data from a survey of 12 US-owned pharmaceutical firms on drug development costs, development phase lengths and failure rates are used to determine estimates of the R&D cost of new drug development by firm size. Firms in the sample are grouped into three size categories, according to their pharmaceutical sales at the beginning of the study period. The D&D cost per new drug approved in the US is shown to decrease with firm size, while sales per new drug approved are shown to increase markedly with firm size. Sales distributions are highly skewed and suggest that firms need to search for blockbuster drugs with above-average returns. The results are consistent with substantial economies of scale in pharmaceutical R&D, particularly at the discovery and preclinical development phases. © 1995, Taylor & Francis Group, LLC. All rights reserved.

dc.identifier.eissn

1466-1829

dc.identifier.issn

1357-1516

dc.identifier.uri

https://hdl.handle.net/10161/6715

dc.publisher

Informa UK Limited

dc.relation.ispartof

International Journal of the Economics of Business

dc.relation.isversionof

10.1080/758519309

dc.title

R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry

dc.type

Journal article

pubs.begin-page

201

pubs.end-page

219

pubs.issue

2

pubs.organisational-group

Duke

pubs.organisational-group

Economics

pubs.organisational-group

Trinity College of Arts & Sciences

pubs.publication-status

Published

pubs.volume

2

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Number 32.pdf
Size:
2.04 MB
Format:
Adobe Portable Document Format